Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUT00206 in recently diagnosed schizophrenia
NCT03164876Phase 1Completed
- Sponsor
- Autifony Therapeutics
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing AUT00206 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-Related Adverse Events at 28 days and Plasma concentrations of AUT00206 at 28 days. Started Apr 2017; status: completed.
02
Drugs
AUT00206
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03164876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164876.